Literature DB >> 6762846

No effect of propranolol and metoprolol on tolbutamide-stimulated insulin-secretion in hypertensive diabetic and non-diabetic patients.

K J Tötterman, L C Groop.   

Abstract

In a double-blind cross-over study, we compared the effects of placebo, propranolol and metoprolol on tolbutamide-stimulated insulin-secretion in 10 non-insulin-dependent hypertensive diabetics and in 10 hypertensive non-diabetic patients. The patients were randomly allocated to two weeks each of treatment with placebo, propranolol 80 mg or metoprolol 100 mg b.i.d. At the end of each period, an intravenous tolbutamide tolerance test (IVTT, 200mg of tolbutamide i.v.) was performed, which caused a significant rise in peripheral insulin levels, leaving blood glucose concentrations unchanged. Tolbutamide-induced insulin-secretion was unaffected by pretreatment with beta-blockers when blood glucose concentrations were unchanged during the test. Since the serum-concentrations achieved with 200 mg of tolbutamide i.v. are similar to those reported during oral tolbutamide therapy, there seems to be no clinically significant interaction between beta-blockers and tolbutamide with respect to insulin-secretion.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6762846

Source DB:  PubMed          Journal:  Ann Clin Res        ISSN: 0003-4762


  3 in total

1.  Adrenergic system and carbohydrate metabolism. Effects of beta-receptor blockade on insulin secretion and peripheral insulin sensitivity in normoglycaemic patients.

Authors:  L A Ferrara; B Capaldo; A Rivellese; S Genovese; C Iovine; P Mastranzo; F Cirillo; M Mancini
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  The effect of nicardipine on glucose and drug-stimulated insulin secretion in normal volunteers.

Authors:  R J Dow; J Baty; T E Isles
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

3.  Effect of beta-blocking drugs on beta-cell function and insulin sensitivity in hypertensive non-diabetic patients.

Authors:  K Tötterman; L Groop; P H Groop; R Kala; E M Tolppanen; F Fyhrquist
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.